Daily Newsletter

15 April 2024

Daily Newsletter

15 April 2024

Adherium’s Smartinhaler gains clearance for use with AstraZeneca devices

The integration of the Hailie Smartinhaler with AstraZeneca’s medications allows real-time data collection for patients.

Archana Rani April 15 2024

Adherium has obtained US Food and Drug Administration (FDA) clearance for the use of its Hailie Smartinhaler with AstraZeneca's Airsupra and Breztri inhalation devices.

This clearance is a significant advancement for asthma and chronic obstructive pulmonary disease (COPD) management.

The Hailie Smartinhaler solution is a cloud-based platform. It utilises bluetooth-enabled sensors that attach to patient inhalers, providing real-time feedback on medication use.

Airsurpa and Breztri are treatments in respiratory care, providing advanced treatment options for patients.

Airsupra is the first FDA-approved rescue medication for asthma, while Breztri is a triple combination therapy for COPD patients.

The compatibility of Adherium's Smartinhaler with these devices allows for 100% coverage for triple therapy inhalers in the US market.

Adherium CEO Dr Paul Mastoridis said: “Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed.

“By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we are bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases. This is just the beginning of our journey to transform respiratory care.”

Adherium said the integration of the Hailie Smartinhaler with these AstraZeneca devices enables real-time data collection and insights into medication usage and inhaler technique.

This data can lead to better adherence and personalised treatment plans, potentially improving patient outcomes and treatment efficacy.

Prominent allergist Dr Bill McCann said: “The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD.

“This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real time, which is invaluable in achieving optimal patient outcomes.”

Immunochemistry Analyzers Market Overview

Per GlobalData, the immunochemistry analyzers market was valued at $1.41 billion in 2023 and is expected to grow at a CAGR of >4% during 2023-2033. Leverage our latest report to develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline, while also tracking device sales in the global and country-specific immunochemistry analyzers market from 2015-2033.

Immunochemistry Analyzers Market Overview

Per GlobalData, the immunochemistry analyzers market was valued at $1.41 billion in 2023 and is expected to grow at a CAGR of >4% during 2023-2033. Leverage our latest report to develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline, while also tracking device sales in the global and country-specific immunochemistry analyzers market from 2015-2033.

Newsletters by sectors

close

Sign up to the newsletter: In Brief

Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close